We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+5.45%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$243M
AUM Growth
+$6.44M
(+2.7%)
Cap. Flow
-$803K
Cap. Flow
% of AUM
-0.33%
Top 10 Holdings %
Top 10 Hldgs %
7.68%
Holding
410
New
55
Increased
156
Reduced
186
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BKCC
BlackRock Capital Investment Corporation
BKCC
|
+$673K |
| 2 |
Zai Lab
ZLAB
|
+$472K |
| 3 |
Stellus Capital Investment Corp
SCM
|
+$422K |
| 4 |
DRD
DRDGold
DRD
|
+$415K |
| 5 |
OXLC
Oxford Lane Capital
OXLC
|
+$359K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AMRS
Amyris Inc.
AMRS
|
+$1.16M |
| 2 |
RUBY
Rubius Therapeutics, Inc
RUBY
|
+$664K |
| 3 |
BioNTech
BNTX
|
+$663K |
| 4 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
+$645K |
| 5 |
Prothena Corp
PRTA
|
+$590K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 27.38% |
| 2 | Real Estate | 18.81% |
| 3 | Energy | 13.29% |
| 4 | Materials | 10.7% |
| 5 | Utilities | 10.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NSL
126
DELISTED
NUVEEN SENIOR INCM FD
NSL
| $538K | 0.22% |
91,006
+24,795
| +37% | +$141K |
|
127
BlackRock Debt Strategies Fund
DSU
$591M
| $535K | 0.22% |
46,713
+13,290
| +40% | +$149K |
|
128
Bain Capital Specialty
BCSF
$802M
| $533K | 0.22% |
34,822
+7,007
| +25% | +$111K |
|
129
Gladstone Investment Corp
GAIN
$635M
| $532K | 0.22% |
36,950
+5,100
| +16% | +$71.2K |
|
130
Ligand Pharmaceuticals
LGND
$6.02B
| $532K | 0.22% |
6,503
-3,351
| -34% | -$279K |
|
131
Ionis Pharmaceuticals
IONS
$9.35B
| $527K | 0.22% |
13,212
+128
| +1% | +$5.01K |
|
132
Regeneron Pharmaceuticals
REGN
$68.8B
| $527K | 0.22% |
944
-303
| -24% | -$154K |
|
133
ADC Therapeutics
ADCT
$146M
| $524K | 0.22% |
21,540
+12,764
| +145% | +$296K |
|
|
MCI
134
Barings Corporate Investors
MCI
$340M
| $524K | 0.22% |
34,476
+5,714
| +20% | +$84.7K |
|
135
Halozyme
HALO
$9.72B
| $523K | 0.22% |
11,515
-3,439
| -23% | -$152K |
|
|
136
Zai Lab
ZLAB
$2.17B
| $520K | 0.21% |
+2,937
| New | +$472K |
|
137
Nuveen Floating Rate Income Fund
JFR
$1.23B
| $519K | 0.21% |
51,821
+14,649
| +39% | +$142K |
|
138
Vertex Pharmaceuticals
VRTX
$121B
| $517K | 0.21% |
2,563
-176
| -6% | -$36.8K |
|
|
JRO
139
DELISTED
Nuveen Floating Rate Income Opportunty Fund
JRO
| $514K | 0.21% |
52,698
+14,838
| +39% | +$142K |
|
|
BPMC
140
DELISTED
Blueprint Medicines
BPMC
| $509K | 0.21% |
5,786
+452
| +8% | +$41.4K |
|
141
Alnylam Pharmaceuticals
ALNY
$36.3B
| $508K | 0.21% |
2,996
-1,725
| -37% | -$253K |
|
142
Incyte
INCY
$23.5B
| $508K | 0.21% |
6,042
-1,162
| -16% | -$96.9K |
|
|
143
BioNTech
BNTX
$22.6B
| $507K | 0.21% |
2,264
-3,515
| -61% | -$663K |
|
|
DCPH
144
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $507K | 0.21% |
13,846
+2,867
| +26% | +$111K |
|
145
Amgen
AMGN
$203B
| $505K | 0.21% |
2,070
-680
| -25% | -$167K |
|
146
BioMarin Pharmaceuticals
BMRN
$11.5B
| $505K | 0.21% |
6,054
-1,496
| -20% | -$119K |
|
|
ALXN
147
DELISTED
Alexion Pharmaceuticals
ALXN
| $505K | 0.21% |
2,749
-1,260
| -31% | -$216K |
|
148
Gilead Sciences
GILD
$161B
| $504K | 0.21% |
7,326
-3,252
| -31% | -$217K |
|
|
SGEN
149
DELISTED
Seagen Inc. Common Stock
SGEN
| $504K | 0.21% |
3,195
-34
| -1% | -$5.05K |
|
150
Karyopharm Therapeutics
KPTI
$168M
| $500K | 0.21% |
3,229
+550
| +21% | +$79.8K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q2 2021 Portfolio in Review
As of Q2 2021, Virtus ETF Advisers held 410 positions worth $243M, up 2.7% from $237M the previous quarter. Its ten largest holdings account for 7.7% of the portfolio.
Virtus ETF Advisers's Q2 2021 filing shows 55 new, 156 increased, 186 reduced and 11 closed positions. Its largest new stake was Zai Lab: 2,937 shares worth $520K. The largest sale was Amyris Inc., an estimated $1.16M.
By sector, the portfolio is most concentrated in Healthcare at 27% of assets, down from 30% a quarter earlier, followed by Real Estate and Energy.
- Virtus ETF Advisers's largest Q2 2021 buy was Zai Lab: 2,937 shares worth $520K.
- Virtus ETF Advisers added most to BlackRock Capital Investment Corporation in Q2 2021, an estimated $673K increase.
- Virtus ETF Advisers's biggest Q2 2021 reduction was Amyris Inc., cutting an estimated $1.16M.
- Virtus ETF Advisers fully exited Five Prime Therapeutics, Inc. in Q2 2021, selling an estimated $645K.
- Virtus ETF Advisers's ten largest holdings make up 7.7% of its $243M portfolio in Q2 2021.
- Virtus ETF Advisers opened 55 new positions and closed 11 in Q2 2021.
- Virtus ETF Advisers's portfolio value rose 2.7% quarter-over-quarter to $243M.
Based on Virtus ETF Advisers's 13F filing for Q2 2021, filed 10 Aug 2021.